A Randomised, Double-blind, Placebo-controlled Parallel Group, Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis.

Trial Profile

A Randomised, Double-blind, Placebo-controlled Parallel Group, Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Nov 2016

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors GW Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 May 2015 Results presented at the Digestive Disease Week 2015.
    • 14 Oct 2014 Primary endpoint of 'percentage of participants achieving remission quantified as a MAYO score of 2 or less (with no subscore1)' has not been met, according to a GW Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top